• MiNK Therapeutics is like **Kite Pharma for universal cell therapies.**
• MiNK Therapeutics is **a biotech like Amgen, but focused on developing ready-made, 'off-the-shelf' cell therapies for cancer and immune diseases.**
• MiNK Therapeutics is **a clinical-stage Genentech, pioneering the next generation of 'off-the-shelf' cell therapies.**

• AGENT-797: An off-the-shelf, allogeneic invariant natural killer T (iNKT) cell therapy currently in Phase 1 clinical trials for the treatment of various myeloma diseases.

The major suppliers for MiNK Therapeutics (INKT) are:

• Agenus Inc. (Symbol: AGEN)
• KBI Biopharma, Inc.

Dr. Jennifer Buell was appointed President and Chief Executive Officer of MiNK Therapeutics in February 2021. She brings over 25 years of biopharmaceutical experience, guiding teams from discovery candidates through clinical development to commercialization. Prior to her role at MiNK, Dr. Buell served as President and Chief Operating Officer at Agenus, transforming it into a global, fully-integrated biotech company with multiple strategic partnerships. She also holds the position of Chairman of the Executive Council at Agenus and has served as a director of Protagenic Therapeutics, Inc. since July 2020.

Christine M. Klaskin oversees the financial reporting for MiNK Therapeutics. She holds the titles of Treasurer, Principal Financial Officer, and Principal Accounting Officer.

Dr. Garo Armen has been the Chairman of MiNK Therapeutics' Board since July 2017 and is a Co-Founder of the company. He is also the Chairman and Chief Executive Officer of Agenus Inc., a company he co-founded in 1994. Dr. Armen played a key role in the successful restructuring of the biopharmaceutical company Elan Corporation, where he served as Chairman of the Board. Additionally, he is currently the Chairman of the Board of Protagenic Therapeutics.

Dr. Marc van Dijk is the Chief Scientific Officer at MiNK Therapeutics. He is credited with spearheading the discovery and development of the company's invariant natural killer T (iNKT) cell platform.

Dr. Terese Hammond serves as the Head of Inflammatory and Pulmonary Diseases for MiNK Therapeutics. Appointed in September 2025, she is responsible for accelerating the company's pipeline into pivotal development in her area of expertise.

Key Risks to MiNK Therapeutics (INKT)

1. Clinical Trial Failure and Regulatory Hurdles: As a clinical-stage biopharmaceutical company, MiNK Therapeutics' success is entirely dependent on the successful outcome of its ongoing and future clinical trials for its lead product candidate, AGENT-797, and other pipeline assets. AGENT-797 is currently in Phase 1 clinical trials for various indications, including solid tumors, multiple myeloma, graft-versus-host disease (GvHD), and critical pulmonary immune failure. There is a high inherent risk of failure at each stage of clinical development, and positive results in early phases do not guarantee success in later, larger trials. Furthermore, the evolving and stringent regulatory landscape for novel cell therapies poses significant hurdles, where any misalignment with guidelines can lead to costly delays or outright rejection, irrespective of therapeutic potential.
2. Financial Viability and Dilution Risk: MiNK Therapeutics is a pre-revenue company operating at a net loss, typical for a clinical-stage biotech. The company will require substantial additional capital to fund its extensive and lengthy research, development, and clinical trial programs through commercialization. Its cash runway was noted to be approximately $14.3 million through 2026 as of Q3 2025. The need to raise additional financing often results in the issuance of new equity, which can significantly dilute the ownership and value for existing shareholders.
3. Intense Competition and Market Acceptance: The biopharmaceutical industry, particularly in advanced cancer treatments and cell therapies, is highly competitive and rapidly evolving. MiNK Therapeutics faces competition from other companies developing allogeneic and autologous cell therapies, as well as conventional treatments. Even if AGENT-797 successfully completes clinical trials and receives regulatory approval, there is no guarantee it will achieve broad market acceptance. Factors such as efficacy, safety profile, manufacturing scalability, cost, pricing pressures, reimbursement policies, and the emergence of superior competing therapies could limit its commercial success. While iNKT cells offer potential advantages like reduced risk of GvHD, achieving comparable persistence to autologous products in allogeneic settings remains a challenge.

MiNK Therapeutics' lead product candidate, AGENT-797, is an invariant natural killer T (iNKT) cell therapy primarily focused on treating various myeloma diseases. Therefore, the most direct addressable market for this product is the multiple myeloma therapeutics market.

Addressable Market for Multiple Myeloma Therapeutics

• Global Market: The global multiple myeloma therapeutics market size was valued at approximately USD 25.4 billion in 2023 and is projected to grow to USD 44.2 billion by 2032.
• North American Market: The North American multiple myeloma therapeutics market is expected to reach USD 20.4 billion by the end of 2032.

Broader Addressable Market for Natural Killer (NK) Cell Therapeutics (including iNKT cells)

As AGENT-797 is an iNKT cell therapy, it also falls within the broader Natural Killer (NK) Cell Therapeutics market.

• Global Market: The global natural killer (NK) cell therapeutics market size was estimated at USD 340.25 million in 2024 and is predicted to increase to approximately USD 9,997.65 million by 2034, expanding at a CAGR of 40.22% from 2025 to 2034.
• North American Market: North America held a significant share of the global NK Cell Therapy market, accounting for over 40% of the global revenue with a market size of USD 40.20 million in 2024.

MiNK Therapeutics, Inc. (INKT), a clinical-stage biopharmaceutical company, is focused on the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies. While currently reporting no revenue, the company's future revenue growth over the next 2-3 years is expected to be driven by key developmental milestones and strategic financial inflows that lay the groundwork for eventual product commercialization.

Here are 3-5 expected drivers of future revenue growth for MiNK Therapeutics:

1. Advancement of Lead Product Candidate AGENT-797 Through Clinical Trials: Successful progression of AGENT-797, their primary iNKT cell therapy candidate, through ongoing and future clinical trials is a critical driver. AGENT-797 is currently in Phase 1 and Phase 2 clinical trials for various indications, including solid tumors like gastric cancer and metastatic testicular cancer, as well as inflammatory lung conditions such as ARDS and graft-versus-host disease (GvHD). Positive clinical data and the achievement of further clinical milestones are anticipated to create "value-inflection" points that can attract additional investment, facilitate future partnerships, and are essential steps towards eventual regulatory approval and market entry, though commercialization is likely beyond the immediate 2-3 year timeframe.
2. Strategic Partnerships and Milestone Payments: New and existing collaborations are expected to contribute to financial inflows and future revenue potential. A recent example is the strategic partnership with C-Further to develop a PRAME-targeted iNKT cell therapy for pediatric cancers. This collaboration is set to provide MiNK Therapeutics with up to $1.1 million in non-dilutive funding for initial studies and preclinical milestones, along with potential double-digit royalties on future sales, representing a direct source of funding and future revenue. Additionally, the company has secured grant funding, such as a Department of Defense STTR Grant, to advance its iNKT programs in GvHD, further bolstering its financial position for development.
3. Expansion of iNKT Cell Therapy Pipeline and New Indications: The company's strategy includes broadening its proprietary iNKT cell therapy platform to address new indications and developing next-generation candidates beyond AGENT-797. This includes the development of PRAME-TCR iNKTs for targeting intracellular cancer targets and MiNK-215 (IL-15 Armored CAR-iNKT) for robust anti-tumor activity. Expanding the pipeline into new areas, such as different types of cancer, pulmonary diseases, and transplant settings, increases the long-term commercial potential and opens opportunities for additional collaborations or licensing agreements, which could lead to future revenue streams.

Share Issuance

• MiNK Therapeutics completed a private placement financing in May 2024, selling 4,640,000 shares of common stock at $1.25 per share, raising $5.8 million to advance clinical trials for MiNK-215.
• The number of outstanding shares has increased significantly, from 2.83 million in 2020 to 4.44 million by February 2026, indicating ongoing share issuances.
• A 1:10 reverse stock split was implemented on January 28, 2025.

Inbound Investments

• In March 2026, MiNK Therapeutics entered into a collaboration with the C-Further pediatric oncology consortium, which includes up to approximately $1.1 million in non-dilutive funding to support IND-enabling work for a PRAME-targeted iNKT cell therapy.
• The company raised $5.8 million in private financing during 2024.
• MiNK Therapeutics entered a research collaboration with Autonomous Therapeutics in October 2024 to develop precision RNA-iNKT therapies for metastatic tumors, with the company prioritizing externally funded clinical trials to advance its programs.